Richard Pazdur, MD
The FDA has approved combination therapy with the BRAF
inhibitor dabrafenib (Tafinlar) and the MEK inhibitor trametinib (Mekinist) for the treatment of patients with unresectable or metastatic BRAF
V600E–positive anaplastic thyroid cancer.
The confirmed overall response rate (ORR) was 69% (11 of 16; 95% CI, 41-89). One patient had a complete response and 10 had partial responses. Seven patients had ongoing responses at the time of the analysis.
... to read the full story